Graftys completed an investment round of €2 million (~US $2.03 million) with its existing shareholders. The company conceives, develops and commercializes injectable biomaterials in more than 25 countries.
Graftys is developing new generations of products for market launch in 2023 and 2024.
Directors Sebastien Genesta, Xavier Ferry and Aurelien Valet jointly stated, “Completion of this investment round will facilitate our work to link GRAFTYS’ commercial performance with innovative capacity to provide important new technology for surgeons, across orthopedic and spine applications. We also remain committed to meeting the highest quality standards, which are always essential in the medical device industry.”
Graftys completed an investment round of €2 million (~US $2.03 million) with its existing shareholders. The company conceives, develops and commercializes injectable biomaterials in more than 25 countries.
Graftys is developing new generations of products for market launch in 2023 and 2024.
Graftys completed an investment round of €2 million (~US $2.03 million) with its existing shareholders. The company conceives, develops and commercializes injectable biomaterials in more than 25 countries.
Graftys is developing new generations of products for market launch in 2023 and 2024.
Directors Sebastien Genesta, Xavier Ferry and Aurelien Valet jointly stated, “Completion of this investment round will facilitate our work to link GRAFTYS’ commercial performance with innovative capacity to provide important new technology for surgeons, across orthopedic and spine applications. We also remain committed to meeting the highest quality standards, which are always essential in the medical device industry.”
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
